New York, NY -- (SBWIRE) -- 01/15/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Sequenom, Inc (NASDAQ:SQNM), Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Oncothyreon Inc (USA) (NASDAQ:ONTY)
Sequenom, Inc (NASDAQ:SQNM) showed a volume of 1.88 million shares by the end of last trade whereas the average volume of the stock remained 1.96 million shares. The stock opened the session at $2.54 but then moved to $2.58. At that price, the stock showed a positive performance of 0.78%. Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural,
Will SQNM Continue To Move Higher? Find Out Here
Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU) opened the session at $6.47 and closed the session at $6.50. The stock showed a positive performance of 0.31% in previous trading session. Mitsubishi UFJ Financial Group, Inc. is a Japan-based company mainly engaged in the banking business. The Company is also involved in trust banking business, security business, credit card business, leasing business and other businesses.
For How Long MTU will fight for Profitability? Read This Trend Analysis report
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) opened the session at $3.56 and closed the session at $3.60. The stock showed a positive performance of 1.12% in previous trading session. Traded with volume of 1.83 million shares in the prior session and the average volume of the stock remained 3.19 million shares. The beta of the stock remained 1.36. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas.
Why Should Investors Buy AVNR After The Recent Gain? Just Go Here and Find Out
Oncothyreon Inc (USA) (NASDAQ:ONTY) the stock advanced 8.99% and finished the session at $2.06. Traded with volume of 1.81 million shares in the prior session and the average volume of the stock remained 692,867 shares. The beta of the stock remained 1.54. Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells.
Will ONTY Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)